PMXSF - Pharmaxis says majority of patients in fibrosis trial see significant improvement

(NewsDirect)

Pharmaxis Ltd(ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive afterreleasing data from a final interim analysis of 10 patients who havecompleted six months’ treatment with its drug PXS-5505 in an openlabel phase 2 clinical trial in patients with the bone marrow cancermyelofibrosis.

The data points to an excellent safety profile and promisingsigns of clinical activity, with 60% of patients who reached thesix-month mark showing improved bone marrow fibrosis scores.

“PXS-5505 continues toshow not only an excellent safety profile but also promising clinicalactivity,” MD Anderson Cancer Center, Department of Leukemiaassistant professor Dr Lucia Masarova said.

“The effect on bonemarrow fibrosis is particularly exciting for a disease likemyelofibrosis, where despite numerous years of research, we do nothave any effective anti-fibrotic drugs.

“It is encouraging to see that majority of 10 patients whocompleted 24 weeks of therapy also had improvements of symptoms andmore importantly, stable or improved blood counts; including in thosepatients with severe thrombocytopenia.”

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.